АкушерствоАнатомияАнестезиологияВакцинопрофилактикаВалеологияВетеринарияГигиенаЗаболеванияИммунологияКардиологияНеврологияНефрологияОнкологияОториноларингологияОфтальмологияПаразитологияПедиатрияПервая помощьПсихиатрияПульмонологияРеанимацияРевматологияСтоматологияТерапияТоксикологияТравматологияУрологияФармакологияФармацевтикаФизиотерапияФтизиатрияХирургияЭндокринологияЭпидемиология

НОВЫЕ БРОНХОЛИТИКИ

Существующие на сегодняшний день бета₂агонисты длительного действия требуют назначения два раза в сутки. Исследования большинства фармацевтических компаний в отношении новых бронхолитических препаратов направлены на создание новых бронходилататоров длительного действия с высоким профилем безопасности. Дополнительный интерес вызывает возможность использования препарата один раз в день, что может значительно улучшить отношение больного к лечению, обеспечивая стойкий 24часовой бронходилатирующий эффект.

В настоящее время проводятся клинические исследования таких препаратов, как GSK159802 и индакатерол, которые являются селективными бета₂адреностимуляторами, предназначенными для приема один раз в сутки.

СПИСОК ЛИТЕРАТУРЫ

1. Barnes P. Respiratory Pharmacology: General Pharmacologic Principles. Murray & Nadel: Textbook of Respiratory Medicine, 3rd ed., 2000, W. B. Saunders Company, p. 232.

2. Guyton AC. Textbook of medical physiology. Philadelphia, 1986.

3. Johnson M. The beta-adrenoceptor.Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 3):S146-53.

4. Barnes P. Respiratory Pharmacology: General Pharmacologic Principles. Murray & Nadel: Textbook of Respiratory Medicine, 3rd ed., 2000, W. B. Saunders Company, p. 232.

5. Barnes P. Effect of beta agonists on inflammatory cells. J. Allergy Clin. Immunol., 1999, 104 (2), 10-17.

6. McGraw DW, Liggett SB. Molecular mechanisms of beta2-adrenergic receptor function and regulation.Proc Am Thorac Soc. 2005;2(4):292-6;

7. Van Veen A, Weller FR, Wierenga EA et. al. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists.

8. Tan KS, Grove A, McLean A, Gnosspelius Y, Hall IP, Lipworth BJ. Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med. 1997 Jul;156(1):28-35.

9. Hanania NA, Sharafkhaneh A, Barber R, Dickey BF. Beta-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med. 2002 May 15;165(10):1353-8.

10. Scola A-M, Chong LK, Suvarna K. et al. Desensitisation of mast cell b2-adrenoceptor-mediated responses by salmeterol and formoterol. British Journal of Pharmacology (2004) 141, 163 - 171

11. Boonsawat W, et al. Respir Med 2003;97:1067 - 1074

12. Bateman ED, Fairall L, Lombardi DM, English R. Respiratory Research 2006, 7:13

13. Sears MR. The evolution of beta2-agonists. Respir Med. 2001 Aug;95 Suppl B:S2-6.

14. Anderson GP, Linden A, Rabe KF. Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 1994;7:569 - 578.

15. Adkins JC, McTavish D. Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma. Drugs. 1997 Aug;54(2):331-54.

16. M. Molimard, E. Naline, Y. Zhang. Long- and short-acting бета2 adrenoceptor agonists: interactions in human contracted bronchi. Eur Respir J 1998; 11: 583 - 588.

17. Hall I.P. бета2-Adrenoceptor Agonists. In Asthma and COPD Basic Mechanisms and Clinical Management, Ed. P. Barnes. 1st ed., 2002, Academic Press.

18. Newman SP, Pavia D, Sheahan NT, et al: Deposition of pressurized aerosols in the lung using radiolabeled particles. Thorax 35:284, 1980.

19. FOWLER SJ, LIPWORTH BJ. Therapeutic equivalence of inhaled salbutamol. Thorax 2000;55:345 - 348.

20. Janson C. Plasma levels and effects of salbutamol after inhaled or i.v. administration in stable asthma. Eur Respir J. 1991 May;4(5):544-50.

21. Lipworth BJ, Clark RA, Fraser CG, et al. The biochemical effects of high-dose inhaled salbutamol in patients with asthma. Eur J Clin Pharmacol 1989;36:357 - 60.

22. Newhouse MT, Chapman KR, McCallum AL, et al. Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. Chest 1996; 110: 595-603

23. Lipworth BJ. Revisiting interactions between hypoxaemia and beta2-agonists in asthma. Thorax 2001;56:506 - 507

24. Au DH, Lemaitre RN, Curtis JR, Smith NL, Psaty BM. The risk of myocardial infarction associated with inhaled b-adrenoceptor agonists. AM J RESPIR CRIT CARE MED 2000;161:827 - 830.

25. Au DH, Curtis JR, Every NR et al. Association Between Inhaled бета-Agonists and the Risk of Unstable Angina and

26.Myocardial Infarction. CHEST 2002; 121:846 - 851

27. Salpeter SR, Buckley NS, Ormiston TM and Salpeter EE. Meta-Analysis: Effect of Long-Acting бета-Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths. Ann Intern Med. 2006;144:904-912.

28. Nelson HS et al. Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Chest 2006;129;15-26

29. Novartis. Drug regulatory affairs: Foradil Aerolizer 12 mcg. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4148B1_02_01-Novartis-Foradil.pdf

30. R.A. Pauwels, M.R. Sears, M. Campbell, C. Villasante, S. Huang, A. Lindh, W. Petermann, M. Aubier, G. Schwabe, T. Bengtsson. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003; 22: 787 - 794.

31. Nemoto T, Ohara-Nemoto Y, Denis M, Gustafsson J-A: The transformed glucocorticoid receptor has a lower steroid-binding affinity than the nontransformed receptor. Biochemistry 1990; 29:1880-1886.

32. Bodine PV, Litwack G: The glucocorticoid receptor and its endogenous regulators. Receptor 1990; 1:83-119.

33. Sher ER, Leung DYM, Surs W, Kam JC, Zeig G, Kamada AK, Harbeck R, Szefler SJ: Steroid resistant asthma: cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994; 93:33-39.

34. Amano Y, Lee SW, Allison AC. Inhibition by glucocorticoids of the formation of interleukin-1 alpha, interleukin-1 beta, and interleukin-6: mediation by decreased mRNA stability. Mol Pharmacol 1993;43:176 - 182

35. Hafezi-Moghadam A, Simoncini T, Yang E, Limbourg FP, Plumier JC, Rebsamen MC, Hsieh CM, Chui DS, Thomas KL, Prorock AJ, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002;8:473 - 479

36. Orchinik M, Murray TF, Moore FL. A corticosteroid receptor in neuronal membranes. Science 1991;252:1848 - 1851.

37. Stellato C. Post-transcriptional and Nongenomic Effects of Glucocorticoids. The Proceedings of the American Thoracic Society 1:255-263 (2004)

38. Reichardt HM, Kaestner KH, Tuckermann J, et al: DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998; 93:531-541.

39. Barnes PJ, Adcock IM: Transcription factors and asthma. Eur. Respir. J. 1998; 12:221-234.

40. Peter J. Barnes, K. Fan Chung, and Clive P. Page Inflammatory Mediators of Asthma: An Update Pharmacol. Rev. 1998 50: 515-596.

41. Woolley KL, Gibson PG, Carty K, Wilson AJ, Twaddell SH, Woolley MJ: Eosinophil apoptosis and the resolution of airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 1996; 154:237-243.

42. John M, Lim S, Seybold J, et al: Inhaled corticosteroids increase IL-10 but reduce MIP-1альфа, GM-CSF and IFN-гамма release from alveolar macrophages in asthma. Am. J. Respir. Crit. Care Med. 1998; 157:256-262.

43. Williams CM, Galli SJ: The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J. Allergy Clin. Immunol. 2000; 105:847-859.

44. Nelson DJ, McWilliam AS, Haining S, Holt PG: Modulation of airway intraepithelial dendritic cells following exposure to steroids. Am. J. Respir. Crit. Care Med. 1995; 151:475-481.

45. Barnes PJ: Mechanism of action of glucocorticoids in asthma. Am. J. Respir. Crit. Care Med. 1996; 154:S21-S27.

46. Kai H, Yoshitake K, Hisatsune A, Kido T, Isohama Y, Takahama K, Miyata T: Dexamethasone suppresses mucus production and MUC-2 and MUC-5AC gene expression by NCI-H292 cells. Am. J. Physiol. 1996; 271:L484-L488.

47. Engel T, Dirksen A, Heinig JH, Nielsen NH, Weeke B, Johansson SA. Single-dose inhaled budesonide in subjects with chronic asthma. Allergy. 1991 Oct;46(7):547-53.

48. Rodrigo GJ. Comparison of inhaled fluticasone with intravenous hydrocortisone in the treatment of adult acute asthma. Am J Respir Crit Care Med. 2005 Jun 1;171(11):1231-6. Epub 2005 Mar 11.

49. Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A. Differences between asthma exacerbations and poor asthma control. Lancet 1999;353(9150):364-9.

50. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999;159(4 Pt 1):1043-51.

51. Meltzer EO, Wenzel S. The efficacy and safety of mometasone furoate delivered via a dry powder inhaler for the treatment of asthma. J Asthma. 2006 Dec;43(10):765-72.

52. Selroos O, Edsbacker S, Hultquist C. Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanation. J Asthma. 2004;41(8):771-90.

53. Toogood JH, Baskerville JC, Jennings B, Lefcoe NM, Johansson SA. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J Allergy Clin Immunol 1982;70(4):288-98.

54. Boudinot FD, D'Ambrosio A, Jusko WJ: Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm 1986; 14:469-493.

55. Masoli M., Holt S., Weatherall M., Beasley R. Dose-response relationship of inhaled budesonide

56.in adult asthma: a meta-analysis. Eur Respir J 2004; 23: 552 - 558.

57. Holt S, Suder A, Weatherall M et al. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001;323:1 - 8

58. Chikanza IC, Kozaci D, Chernajovsky Y. The molecular and cellular basis of corticosteroid resistance. J Endocrinol. 2003 Dec;179(3):301-10.

59. Pedersen, S., and O. R. Hansen. 1995. Budesonide treatment of moderate and severe asthma in children: a dose-response study. J. Allergy Clin. Immunol. 95:29 - 33.

60. Alving, K., J. O. N. Lundberg, and S. L. Nordvall. 1995. Dose-dependent reduction of exhaled nitric oxide in asthmatic children by in haled steroids (abstract). Am. J. Respir. Crit. Care Med. 151:A129.

61. Malmstrom, K, Rodriguez-Gomez, G, Guerra, J, et al Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999;130,487-495

62. Phillipps GH, Bailey EJ, Bain BM, et al. Synthesis and structure-activity relationships in a series of anti-inflammatory corticosteroid analogues, halomethyl androstane-17beta-carbothioates and -17beta-carboselenoates. J Med Chem 1994; 37:3717 - 3729

63. Belvisi M, Bundschuh D, Stoeck M, et al. Ciclesonide, a novel on site activatedinhaled corticosteroid with potent anti-inflammatory actions in the airways [abstract]. J Allergy Clin Immunol 2002; 109(suppl):59

64. Chapman KR, Patel P, D’Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005; 60:330 - 337

65. Systematic Review of the Evidence Regarding Potential Complications of Inhaled Corticosteroid Use in Asthma. Chest 2003;124;2329-2340

66. Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK: Frequency of voice problems and cough in patients using pressurised aersosol inhaled steroid preparations. Eur. Respir. J. 1995; 8:590-592.

67. Toogood JA, Jennings B, Greenway RW, Chung L: Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J. Allergy Clin. Immunol. 1980; 65:145-153.

68. Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. New England Journal of Medicine. 2000;343:1054-1063.

69. Agertoft L, et al. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. New England Journal of Medicine. 2000;343:1064-1069.

70. Poolson JB, Kazanowski JJ, Goldman AL, Szentivanyi A: Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline. Clin. Exp. Pharmacol. Physiol. 1978; 5:535-539.

71. Pauwels RA, Joos GF: Characterization of the adenosine receptors in the airways. Arch. Int. Pharmacodyn. Ther. 1995; 329:151-156.

72. Ishizaki T, Minegishi A, Morishita A, et al: Plasma catecholamine concentrations during a 72 hour aminophylline infusion in children with acute asthma. J. Allergy Clin. Immunol. 1988; 92:146-154.

73. Horrobin DF, Manku MS, Franks DJ, Hamet P: Methylxanthine phosphodiesterase inhibitors behave as prostaglandin antagonists in a perfused rat mesenteric artery preparation. Prostaglandins 1977; 13:33-40.

74. Spatafora M, Chiappara G, Merendino AM, D’Amico D, Bellia V, Bonsignore G: Theophylline suppresses the release of tumour necrosis factor-alpha by blood monocytes and alveolar macrophages. Eur. Respir. J. 1994; 7:223-228.

75. Aubier M, De Troyer A, Sampson M, Macklem PT, Roussos Ch: Aminophylline improves diaphragmatic contractility. N. Engl. J. Med. 1981; 305:249-252.

76. Jusko WJ, Gardner MJ, Mangiore A, Schentag JJ, Kopp JR, Vance JW: Factors affecting aminophylline clearance: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates and ethanol. J. Pharm. Sci. 1979; 68:1358-1366.

77. Аharony D. Pharmacology of leukotriene receptor antagonists. // Am. J. Respir. Crit. Care Med. - 1998 Jun. - V. 157, 6 Pt 2. - P. 214-218

78. Devillier P., Millart H., Advenier C. The anti-leukotrienes: their use in asthma. // Rev. Med. Brux. - 1997 Sep. - V. 18, 4. - P. 279-285.

79. Drazen J.M. Pharmacology of leukotriene receptor antagonists and 5-lipoxigenase inhibitors in the management of asthma. // Pharmacotherapy. - 1997 Jan. - V. 17, 1 Pt 2. - P. 22-30.

80. O'Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest. 1997 Feb;111(2 Suppl):27S-34S

81. Felder CC. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J 1995;9:619 - 625.

82. Koumis T, Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther. 2005 Apr;27(4):377-92.

83. Somand H, Remington TL. Tiotropium: a bronchodilator for chronic obstructive pulmonary disease. Ann Pharmacother. 2005 Sep;39(9):1467-75. Epub 2005 Jul 19.

84. Proskocil BJ and Fryer AD бета2-Agonist and Anticholinergic Drugs in the Treatment of Lung Disease. Proc Am Thorac Soc Vol 2. pp 305 - 310, 2005

85. Liu J, Lester P, Builder S, et al. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995;34(33):10474 - 82.

86. Boushey H. Experiences with monoclonal antibody therapy for allergic asthma. J Allergy Clin Immunol 2001;108(2 Suppl):S79

87. Liu J, Lester P, Builder S, Shire SJ. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry. 1995;34:10474-10482.

88. Presta L, Shields R, O'Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem. 1994;269:26368-26373.

89. Sechi S, Roller PP, Willette-Brown J, Kinet JP. A conformational rearrangement upon binding of IgE to its high affinity receptor. J Biol Chem. 1996;271:19256-19263.

90. Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol. 2000;18:157-162.

91. Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol. 1995;107:308-312.

92. Schmidt D, Watson N, Reulmann E, Magnussen H, Rabe KF. Serum IgE levels predict human

93.airway reactivity in vitro. Clin Exp Allergy 2000;30(2):233 - 41.

94. Brownell J, Casale TB Anti-IgE therapy. Immunol Allergy Clin N Am 24 (2004) 551 - 568

95. Boulet LP, Chapman KR, Cote J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergeninduced early asthmatic response. Am J Respir CritCare Med 1997;155(6):1835 - 40.

96. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108(2):184 - 90.

97. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children (Review). The Cochrane Library 2007, Issue 1

98. Nowak D. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Respir Med. 2006 Nov;100(11):1907-17. Epub 2006

99. Global Strategy for Asthma Management and Prevention. REVISED 2006. The GINA reports are available on www.ginasthma.org.

100. Genentech, Inc. Xolair(R) (omalizumab for subcutaneous use) package insert. South San Francisco, Calif; June 2003.

101. Marian M, Sun Y-N, Sinclair BS, et al. Clinical pharmacokinetics (PK) and IgE pharmacodynamics (PD) of omalizumab, a recombinant humanized monoclonal antibody to IgE. Clin Pharmacol Ther. 2001;69:P7.

102. Bisberg D, Froehlich J, Schoenhoff M, Mendelson J. Multiple administrations of the anti-IgE recombinant humanized monoclonal antibody E25 (rhuMAb-E25) reduces free IgE levels in a dose dependent manner in adolescents and children with moderate to severe allergic asthma. J Clin Pharmacol. 1996;36:859.

103. Schoenwetter W, Gupta N, Liu J, van As A. Omalizumab, an anti-immunoglobulin E antibody, is well tolerated in patients with allergic diseases of the airways [abstract]. Chest 2002; 122(4 Suppl):Abst P118.

104. Genentech, Inc. Prescribing information: summary of product characteristics. Available at: http://

105.www.xolair.com. Accessed January 3, 2003.

106. Guevara JP, Ducharme FM, Keren R, Nihtianova S, Zorc J. Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003558.

107. Амелина Е. Л. Чучалин А.Г. Муковисцидоз: современный подход к диагностике и лечению. РМЖ, т. 5, 17, 1997.

108. Davies J, Trindale M, Wallis C, Rosenthal M, Bush A. The clinical use of rhDNAse. Pediatr Pulmonol Suppl. 1997;16:273-4.

109. Greenfeder S, Umland SP, Cuss FM, et al. Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir Res 2001;2(2):71 - 9.

110. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness and the late asthmatic response. Lancet 2000;356(9248):2144 - 8.

111. Kay AB, Klion AD. Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome. Immunol Allergy Clin North Am 2004;24(4):645 - 66.

112. Steinke JW, Borish L. TH2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res 2001;2(2):66 - 70.

113. Holgate ST. Cytokine and anti-cytokine therapy for thetreatment of asthma and allergic disease. Cytokine 2004;28(4 - 5):152 - 7.

114. Khalil C, Brown D, Chumney-Malacara J, et al. Infliximab therapy for rheumatoid arthritis (RA) induced significant control of asthma in patients with both RA and asthma or asthma/COPD in addition to improving RA status. J Allergy Clin Immunol 2002; 109:A741.

115. Ying S, Robinson DS, Meng Q, et al. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma: association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 1997;27(12):3507 - 16.

116. Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001;108(5 Part 1):671 - 80.

117. Grootendorst DC, Rabe KF. Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. Curr Opin Allergy Clin Immunol 2002;2(1):61 - 7.

document:

$pr:

version: 01-2007.1

codepage: windows-1251

type: klinrek

id: kli12173553

: 04.1. ОБЩАЯ И ЧАСТНАЯ ПАТОЛОГИЯ ЛЕГКИХ

meta:

author:

fio[ru]: А.Л. Черняев, М.В. Самсонова

codes:

next:

type: dklinrek

code: I.IV

type: dkli00023

Дата добавления: 2015-01-18 | Просмотры: 1114 | Нарушение авторских прав